<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35535500</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention.</ArticleTitle>
        <Pagination>
          <StartPage>790</StartPage>
          <EndPage>805</EndPage>
          <MedlinePgn>790-805</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2072743</ELocationID>
        <Abstract>
          <AbstractText>Chronic kidney disease (CKD) is a severe clinical syndrome with significant socioeconomic impact worldwide. Orderly energy metabolism is essential for normal kidney function and energy metabolism disorders are increasingly recognized as an important player in CKD. Energy metabolism disorders are characterized by ATP deficits and reactive oxygen species increase. Oxygen and mitochondria are essential for ATP production, hypoxia and mitochondrial dysfunction both affect the energy production process. Renin-angiotensin and adenine signaling pathway also play important regulatory roles in energy metabolism. In addition, disturbance of energy metabolism is a key factor in the development of hereditary nephropathy such as autosomal dominant polycystic kidney disease. Currently, drugs with clinically clear renal function protection, such as Angiotensin II Type 1 receptor blockers and fenofibrate, have been proven to improve energy metabolism disorders. The sodium-glucose co-transporter inhibitors 2 that can mediate glucose metabolism disorders not only delay the progress of diabetic nephropathy, but also have significant protective effects in non-diabetic nephropathy. Hypoxia-inducible factor enhances ATP production to the kidney by improving renal oxygen supply and increasing glycolysis, and the mitochondria targeted peptides (SS-31) plays a protective role by stabilizing the mitochondrial inner membrane. Moreover, several drugs are being studied and are predicted to have potential renal protective properties. We propose that the regulation of energy metabolism represents a promising strategy to delay the progression of CKD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xuyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Huasheng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shao</LastName>
            <ForeName>Leping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>8L70Q75FXE</RegistryNumber>
          <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051436" MajorTopicYN="Y">Renal Insufficiency, Chronic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Energy metabolism</Keyword>
        <Keyword MajorTopicYN="N">chronic kidney disease</Keyword>
        <Keyword MajorTopicYN="N">drug intervention</Keyword>
        <Keyword MajorTopicYN="N">hypoxia</Keyword>
        <Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>4</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35535500</ArticleId>
        <ArticleId IdType="pmc">PMC9103584</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2072743</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lv JC, Zhang LX.. 
Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:790–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Friederich-Persson M, Thörn E, Hansell P, et al. . 
Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension. 2013;62(5):914–919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3867444</ArticleId>
            <ArticleId IdType="pubmed">24019401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey JN.
Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens. 2003;12(3):317–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12698072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soltoff SP.
ATP and the regulation of renal cell function. Annu Rev Physiol. 1986;48:9–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3010834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rich PR.
The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans. 2003;31(Pt 6):1095–1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14641005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes JM, Thorburn DR.. 
Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29456246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balaban RS, Mandel LJ, Soltoff SP, et al. . 
Coupling of active ion transport and aerobic respiratory rate in isolated renal tubules. Proc Natl Acad Sci USA. 1980;77(1):447–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC348288</ArticleId>
            <ArticleId IdType="pubmed">6244559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chance B, Williams GR.. 
The respiratory chain and oxidative phosphorylation. Adv Enzymol Relat Subj Biochem. 1956;17:65–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13313307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer G, Corrigan G, Fredrickson J, et al. . 
Renal blood flow: measurement in vivo with rapid spiral MR imaging. Radiology. 1998;208(3):729–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9722853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer G, Noorbehesht B, Pelc N, et al. . 
Normal renal blood flow measurement using phase-contrast cine magnetic resonance imaging. Invest Radiol. 1992;27(6):465–470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1607260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricksten SE, Bragadottir G, Redfors B.. 
Renal oxygenation in clinical acute kidney injury. Crit Care. 2013;17(2):221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672481</ArticleId>
            <ArticleId IdType="pubmed">23514538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nourbakhsh N, Singh P.. 
Role of renal oxygenation and mitochondrial function in the pathophysiology of acute kidney injury. Nephron Clin Pract. 2014;127(1–4):149–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5540439</ArticleId>
            <ArticleId IdType="pubmed">25343840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiil F, Aukland K, Refsum HE.. 
Renal sodium transport and oxygen consumption. Am J Physiol. 1961;201:511–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13755902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Connor PM.
Renal oxygen delivery: matching delivery to metabolic demand. Clin Exp Pharmacol Physiol. 2006;33(10):961–967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17002675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitehouse T, Stotz M, Taylor V, et al. . 
Tissue oxygen and hemodynamics in renal medulla, cortex, and corticomedullary junction during hemorrhage-reperfusion. Am J Physiol Renal Physiol. 2006;291(3):F647–F653</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16525156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy MN, Sauceda G.. 
Diffusion of oxygen from arterial to venous segments of renal capillaires. Am J Physiol. 1959;196(6):1336–1339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13661371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngo JP, Kar S, Kett MM, et al. . 
Vascular geometry and oxygen diffusion in the vicinity of artery-vein pairs in the kidney. Am J Physiol Renal Physiol. 2014;307(10):F1111–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25209866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schurek HJ, Jost U, Baumgärtl H, et al. . 
Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. Am J Physiol. 1990;259(6 Pt 2):F910–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2260684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welch WJ, Baumgärtl H, Lübbers D, et al. . 
Nephron pO2 and renal oxygen usage in the hypertensive rat kidney. Kidney Int. 2001;59(1):230–237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11135075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acín-Pérez R, Fernández-Silva P, Peleato ML, et al. . 
Respiratory active mitochondrial supercomplexes. Mol Cell. 2008;32(4):529–539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19026783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emma F, Montini G, Parikh SM, et al. . 
Mitochondrial dysfunction in inherited renal disease and acute kidney injury. Nat Rev Nephrol. 2016;12(5):267–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5469549</ArticleId>
            <ArticleId IdType="pubmed">26804019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turunen M, Olsson J, Dallner G.. 
Metabolism and function of coenzyme Q. Biochim Biophys Acta. 2004;1660(1–2):171–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14757233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rich PR, Maréchal A.. 
The mitochondrial respiratory chain. Essays Biochem. 2010;47:1–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20533897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans RG, Gardiner BS, Smith DW, et al. . 
Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis. Am J Physiol Renal Physiol. 2008;295(5):F1259–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18550645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duann P, Lin PH.. 
Mitochondria damage and kidney disease. Adv Exp Med Biol. 2017;982:529–551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8049117</ArticleId>
            <ArticleId IdType="pubmed">28551805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solini A, Usuelli V, Fiorina P.. 
The dark side of extracellular ATP in kidney diseases. J Am Soc Nephrol. 2015;26(5):1007–1016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4413770</ArticleId>
            <ArticleId IdType="pubmed">25452669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts VS, Cowan PJ, Alexander SI, et al. . 
The role of adenosine receptors A2A and A2B signaling in renal fibrosis. Kidney Int. 2014;86(4):685–692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25054776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies RI, Booth JWR, Mullins JJ, et al. . 
Hyperglycemia-induced renal P2X7 receptor activation enhances diabetes-related injury. EBioMedicine. 2017;19:73–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5440600</ArticleId>
            <ArticleId IdType="pubmed">28434946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kretschmar C, Oyarzún C, Villablanca C, et al. . 
Reduced adenosine uptake and its contribution to signaling that mediates profibrotic activation in renal tubular epithelial cells: implication in diabetic nephropathy. PLOS One. 2016;11(1):e0147430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4726618</ArticleId>
            <ArticleId IdType="pubmed">26808537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Zhang Y, Wang W, et al. . 
Elevated ecto-5'-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension. Circ Res. 2013;112(11):1466–1478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3886128</ArticleId>
            <ArticleId IdType="pubmed">23584256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rangan G.
Role of extracellular ATP and P2 receptor signaling in regulating renal cyst growth and interstitial inflammation in polycystic kidney disease. Front Physiol. 2013;4(218):218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3744908</ArticleId>
            <ArticleId IdType="pubmed">23966953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hovater MB, Olteanu D, Welty EA, et al. . 
Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts. Purinergic Signal. 2008;4(2):109–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2377320</ArticleId>
            <ArticleId IdType="pubmed">18438719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dwyer KM, Kishore BK, Robson SC.. 
Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol. 2020;16(9):509–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32641760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solini A, Menini S, Rossi C, et al. . 
The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol. 2013;231(3):342–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23843215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roa H, Gajardo C, Troncoso E, et al. . 
Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett. 2009;583(19):3192–3198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19737558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson PF, Farrell FX, Morel D, et al. . 
Adenosine signaling increases proinflammatory and profibrotic mediators through activation of a functional adenosine 2B receptor in renal fibroblasts. Ann Clin Lab Sci. 2016;46(4):339–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27466291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckardt KU, Bernhardt WM, Weidemann A, et al. . 
Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl. 2005;68(99):S46–S51.</Citation>
        </Reference>
        <Reference>
          <Citation>Eckardt KU, Rosenberger C, Jürgensen JS, et al. . 
Role of hypoxia in the pathogenesis of renal disease. Blood Purif. 2003;21(3):253–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12784052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nangaku M.
Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16291837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krolewski AS.
Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38(6):954–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4439536</ArticleId>
            <ArticleId IdType="pubmed">25998286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin YC, Chang YH, Yang SY, et al. . 
Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29486908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nespoux J, Vallon V.. 
SGLT2 inhibition and kidney protection. Clin Sci. 2018;132(12):1329–1339.</Citation>
        </Reference>
        <Reference>
          <Citation>O'Neill J, Fasching A, Pihl L, et al. . 
Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309(3):F227–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26041448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honda T, Hirakawa Y, Nangaku M.. 
The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract. 2019;38(4):414–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6913586</ArticleId>
            <ArticleId IdType="pubmed">31558011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler S, Huang H.. 
Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats. JASN. 2002;13(7):1788–1794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12089374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sas KM, Kayampilly P, Byun J, et al. . 
Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight. 2016;1(15):e86976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5033761</ArticleId>
            <ArticleId IdType="pubmed">27699244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu S, Wang Y, Zheng M, et al. . 
Hypoxia and hypoxia-inducible factors in kidney injury and repair. Cells. 2019;8(3):207.</Citation>
        </Reference>
        <Reference>
          <Citation>Laustsen C, Lycke S, Palm F, et al. . 
High altitude may alter oxygen availability and renal metabolism in diabetics as measured by hyperpolarized [1-(13)C]pyruvate magnetic resonance imaging. Kidney Int. 2014;86(1):67–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24352155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manotham K, Tanaka T, Matsumoto M, et al. . 
Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int. 2004;65(3):871–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmarakby AA, Sullivan JC.. 
Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20718759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T, Hanafusa N, Ingelfinger JR, et al. . 
Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF1-mediated upregulation of bax. Biochem Biophys Res Commun. 2003;309(1):222–231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12943686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobori H, Nangaku M, Navar LG, et al. . 
The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17878513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi D, Gordon KL, Polinsky P, et al. . 
Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension. 1999;33(4):1013–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10205240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friederich-Persson M, Persson P.. 
Mitochondrial angiotensin II receptors regulate oxygen consumption in kidney mitochondria from healthy and type 1 diabetic rats. Am J Physiol Renal Physiol. 2020;318(3):F683–f688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31904285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klahr S, Morrissey JJ.. 
The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7–S14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10828755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín-Hernández E, García-Silva MT, Vara J, et al. . 
Renal pathology in children with mitochondrial diseases. Pediatr Nephrol. 2005;20(9):1299–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15977024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris PC, Torres VE.. 
Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124(6):2315–2324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4089452</ArticleId>
            <ArticleId IdType="pubmed">24892705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halvorson CR, Bremmer MS, Jacobs SC.. 
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis. 2010;3:69–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3108786</ArticleId>
            <ArticleId IdType="pubmed">21694932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CC, Kurashige M, Liu Y, et al. . 
A cleavage product of polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci Rep. 2018;8(1):2743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5807443</ArticleId>
            <ArticleId IdType="pubmed">29426897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padovano V, Kuo IY, Stavola LK, et al. . 
The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function. Mol Biol Cell. 2017;28(2):261–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5231895</ArticleId>
            <ArticleId IdType="pubmed">27881662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G, Galluzzi L, Brenner C.. 
Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87(1):99–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17237344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menezes LF, Lin CC, Zhou F, et al. . 
Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EBioMedicine. 2016;5:183–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4816756</ArticleId>
            <ArticleId IdType="pubmed">27077126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warner G, Hein KZ, Nin V, et al. . 
Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol. 2016;27(5):1437–1447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4849816</ArticleId>
            <ArticleId IdType="pubmed">26538633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi Z, Song Y, Cao X, et al. . 
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease. Nat Metab. 2020;2(8):717–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32694829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hackl A, Mehler K, Gottschalk I, et al. . 
Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities. Pediatr Nephrol. 2017;32(5):791–800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28083701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinzii CM, López LC, Gilkerson RW, et al. . 
Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. Faseb J. 2010;24(10):3733–3743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2996902</ArticleId>
            <ArticleId IdType="pubmed">20495179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishikawa T, Edelstein D, Du XL, et al. . 
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787–790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10783895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beisswenger PJ, Howell SK, Nelson RG, et al. . 
Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans. 2003;31(Pt 6):1358–1363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14641063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basile DP, Bonventre JV, Mehta R, ADQI XIII Work Group, et al.. 
Progression after AKI: Understanding maladaptive repair processes to predict and identify therapeutic treatments. J Am Soc Nephrol. 2016;27(3):687–697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4769207</ArticleId>
            <ArticleId IdType="pubmed">26519085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manny J, Livni N, Schiller M, et al. . 
Structural changes in the perfused canine kidney exposed to the direct action of endotoxin. Isr J Med Sci. 1980;16(3):153–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7390755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch EAT, Nakhoul R, Nakhoul F, et al. . 
Autophagy in diabetic nephropathy: a review. Int Urol Nephrol. 2020;52(9):1705–1712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32661628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duann P, Lianos EA, Ma J, et al. . 
Autophagy, innate immunity and tissue repair in acute kidney injury. IJMS. 2016;17(5):662.</Citation>
        </Reference>
        <Reference>
          <Citation>Kawakami T, Gomez IG, Ren S, et al. . 
Deficient autophagy results in mitochondrial dysfunction and FSGS. J Am Soc Nephrol. 2015;26(5):1040–1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4413752</ArticleId>
            <ArticleId IdType="pubmed">25406339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes JM, Coughlan MT, Cooper ME.. 
Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57(6):1446–1454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18511445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uesugi R, Ishii S, Matsuura A, et al. . 
Labeling and measuring stressed mitochondria using a PINK1-based ratiometric fluorescent sensor. J Biol Chem. 2021;297(5):101279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8560995</ArticleId>
            <ArticleId IdType="pubmed">34624312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindblom RSJ, Higgins GC, Nguyen TV, et al. . 
Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. Clin Sci. 2020;134(2):239–259.</Citation>
        </Reference>
        <Reference>
          <Citation>Nangaku M, Hirakawa Y, Mimura I, et al. . 
Epigenetic changes in the acute kidney injury-to-chronic kidney disease transition. Nephron. 2017;137(4):256–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28595179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillard P, Schnell O, Groop PH.. 
The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Res Clin Pract. 2020;170:108462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32971152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang YS, Zhao YH, Zhong Y, et al. . 
Neferine inhibits LPS-ATP-induced endothelial cell pyroptosis via regulation of ROS/NLRP3/caspase-1 signaling pathway. Inflamm Res. 2019;68(9):727–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31172209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Raoof M, Chen Y, et al. . 
Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2843437</ArticleId>
            <ArticleId IdType="pubmed">20203610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerich JE.
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4232006</ArticleId>
            <ArticleId IdType="pubmed">20546255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinn PG, Yeagley D.. 
Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(4):423–437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16375695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gatica R, Bertinat R, Silva P, et al. . 
Altered expression and localization of insulin receptor in proximal tubule cells from human and rat diabetic kidney. J Cell Biochem. 2013;114(3):639–649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23059533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magee GM, Bilous RW, Cardwell CR, et al. . 
Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52(4):691–697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19198800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallon V, Thomson SC.. 
Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351–375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3807782</ArticleId>
            <ArticleId IdType="pubmed">22335797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahmoune H, Thompson PW, Ward JM, et al. . 
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16306358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osorio H, Bautista R, Rios A, et al. . 
Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract. 2009;86(3):e46–e49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19800706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ, Huber TB, Isermann B, et al. . 
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29654297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heerspink HJL, Kosiborod M, Inzucchi SE, et al. . 
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29735306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piperidou A, Sarafidis P, Boutou A, et al. . 
The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(7):1334–1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31145707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarafidis P, Ferro CJ, Morales E, et al. . 
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30753708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heerspink HJ, Perkins BA, Fitchett DH, et al. . 
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27470878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonnet F, Scheen AJ.. 
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44(6):457–464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30266577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sano M, Goto S.. 
Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–1987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31009585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghanim H, Abuaysheh S, Hejna J, et al. . 
Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):dgaa057.</Citation>
        </Reference>
        <Reference>
          <Citation>Darawshi S, Yaseen H, Gorelik Y, et al. . 
Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors. Ren Fail. 2020;42(1):836–844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7472507</ArticleId>
            <ArticleId IdType="pubmed">32787602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ali BH, Al Salam S, Al Suleimani Y, et al. . 
Effects of the SGLT-2 inhibitor canagliflozin on adenine-induced chronic kidney disease in rats. Cell Physiol Biochem. 2019;52(1):27–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30790503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chobanian AV, Bakris GL, Black HR, et al. . 
The seventh report of the joint national committee on prevention. Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289(19):2560–2572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12748199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mancia G, De Backer G, Dominiczak A, European Society of Cardiology, et al.. 
2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17563527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogihara T, Kikuchi K, Matsuoka H, Japanese Society of Hypertension Committee, et al.. 
The japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19300436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K, Hu J, Luo T, et al. . 
Effects of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(3):768–779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29794446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer SC, Mavridis D, Navarese E, et al. . 
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385(9982):2047–2056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26009228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Izuhara Y, Nangaku M, Inagi R, et al. . 
Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16(12):3631–3641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16236804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imanishi M, Yoshioka K, Konishi Y, et al. . 
Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia. 1999;42(8):999–1005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10491761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kario K, Okada K, Kato M, et al. . 
Hour blood Pressure-Lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139(18):2089–2097.</Citation>
        </Reference>
        <Reference>
          <Citation>Kojima N, Williams JM, Takahashi T, et al. . 
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013;345(3):464–472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3657104</ArticleId>
            <ArticleId IdType="pubmed">23492941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desbats MA, Lunardi G, Doimo M, et al. . 
Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis. 2015;38(1):145–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25091424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacconi S, Trevisson E, Salviati L, et al. . 
Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord. 2010;20(1):44–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19945282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montero R, Grazina M, López-Gallardo E, Coenzyme Q10 Deficiency Study Group, et al. . 
Coenzyme Q10 deficiency in mitochondrial DNA depletion syndromes. Mitochondrion. 2013;13(4):337–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23583954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragaki K, Chaussenot A, Benoist JF, et al. . 
Coenzyme Q10 defects may be associated with a deficiency of Q10-independent mitochondrial respiratory chain complexes. Biol Res. 2016;49:4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4705639</ArticleId>
            <ArticleId IdType="pubmed">26742794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montini G, Malaventura C, Salviati L.. 
Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med. 2008;358(26):2849–2850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18579827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López LC, Quinzii CM, Area E, et al. . 
Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLOS One. 2010;5(7):e11897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2912846</ArticleId>
            <ArticleId IdType="pubmed">20689595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Martín JM, Salviati L, Trevisson E, et al. . 
Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. Hum Mol Genet. 2007;16(9):1091–1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4345105</ArticleId>
            <ArticleId IdType="pubmed">17374725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Yue Z, Lin H, et al. . 
COQ2 mutation associated isolated nephropathy in two siblings from a Chinese pedigree. Ren Fail. 2021;43(1):97–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7801106</ArticleId>
            <ArticleId IdType="pubmed">33397173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Tang D, Zou Y, et al. . 
A mitochondrial-targeted peptide ameliorated podocyte apoptosis through a HOCl-alb-enhanced and mitochondria-dependent signalling pathway in diabetic rats and in vitro. J Enzyme Inhib Med Chem. 2019;34(1):394–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6327984</ArticleId>
            <ArticleId IdType="pubmed">30734599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birk AV, Liu S, Soong Y, et al. . 
The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3736700</ArticleId>
            <ArticleId IdType="pubmed">23813215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frey TG, Mannella CA.. 
The internal structure of mitochondria. Trends Biochem Sci. 2000;25(7):319–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10871882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claypool SM.
Cardiolipin, a critical determinant of mitochondrial carrier protein assembly and function. Biochim Biophys Acta. 2009;1788(10):2059–2068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2757529</ArticleId>
            <ArticleId IdType="pubmed">19422785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiebish MA, Yang K, Sims HF, et al. . 
Myocardial regulation of lipidomic flux by cardiolipin synthase: setting the beat for bioenergetic efficiency. J Biol Chem. 2012;287(30):25086–25097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3408154</ArticleId>
            <ArticleId IdType="pubmed">22584571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfeiffer K, Gohil V, Stuart RA, et al. . 
Cardiolipin stabilizes respiratory chain supercomplexes. J Biol Chem. 2003;278(52):52873–52880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14561769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Mileykovskaya E, Dowhan W.. 
Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J Biol Chem. 2002;277(46):43553–43556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12364341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rytömaa M, Kinnunen PK.. 
Evidence for two distinct acidic phospholipid-binding sites in cytochrome c. J Biol Chem. 1994;269(3):1770–1774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8294426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rytömaa M, Kinnunen PK.. 
Reversibility of the binding of cytochrome c to liposomes. Implications for lipid-protein interactions. J Biol Chem. 1995;270(7):3197–3202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7852404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanske J, Toffey JR, Morenz AM, et al. . 
Conformational properties of cardiolipin-bound cytochrome c. Proc Natl Acad Sci USA. 2012;109(1):125–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3252944</ArticleId>
            <ArticleId IdType="pubmed">22190488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kagan VE, Borisenko GG, Tyurina YY, et al. . 
Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. Free Radic Biol Med. 2004;37(12):1963–1985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15544916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinibaldi F, Fiorucci L, Patriarca A, et al. . 
Insights into cytochrome c-cardiolipin interaction. Role played by ionic strength. Biochemistry. 2008;47(26):6928–6935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18540683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducasa GM, Mitrofanova A, Mallela SK, et al. . 
ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. J Clin Invest. 2019;129(8):3387–3400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6668702</ArticleId>
            <ArticleId IdType="pubmed">31329164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birk AV, Chao WM, Bracken C, et al. . 
Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017–2028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3976619</ArticleId>
            <ArticleId IdType="pubmed">24134698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukuda R, Zhang H, Kim JW, et al. . 
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007;129(1):111–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17418790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruber M, Hu CJ, Johnson RS, et al. . 
Acute postnatal ablation of hif-2alpha results in anemia. Proc Natl Acad Sci USA. 2007;104(7):2301–2306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1892942</ArticleId>
            <ArticleId IdType="pubmed">17284606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skuli N, Liu L, Runge A, et al. . 
Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood. 2009;114(2):469–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2714217</ArticleId>
            <ArticleId IdType="pubmed">19439736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skuli N, Majmundar AJ, Krock BL, et al. . 
Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes. J Clin Invest. 2012;122(4):1427–1443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3314446</ArticleId>
            <ArticleId IdType="pubmed">22426208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shih HM, Wu CJ, Lin SL.. 
Physiology and pathophysiology of renal erythropoietin-producing cells. J Formos Med Assoc. 2018;117(11):955–963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29655605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang LE, Arany Z, Livingston DM, et al. . 
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996;271(50):32253–32259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8943284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kallio PJ, Pongratz I, Gradin K, et al. . 
Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the ARNT transcription factor. Proc Natl Acad Sci U S A. 1997;94(11):5667–5672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC20836</ArticleId>
            <ArticleId IdType="pubmed">9159130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahimi-Horn C, Mazure N, Pouysségur J.. 
Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal. 2005;17(1):1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15451019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaakkola P, Mole DR, Tian YM, et al. . 
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11292861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivas V, Zhang LP, Zhu XH, et al. . 
Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun. 1999;260(2):557–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10403805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berra E, Benizri E, Ginouvès A, et al. . 
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. Embo J. 2003;22(16):4082–4090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC175782</ArticleId>
            <ArticleId IdType="pubmed">12912907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaelin
WG, Jr., Ratcliffe PJ.. 
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18498744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lando D, Peet DJ, Whelan DA, et al. . 
Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295(5556):858–861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11823643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahon PC, Hirota K, Semenza GL.. 
FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15(20):2675–2686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC312814</ArticleId>
            <ArticleId IdType="pubmed">11641274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill P, Shukla D, Tran MG, et al. . 
Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2008;19(1):39–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2391027</ArticleId>
            <ArticleId IdType="pubmed">18178798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Schley G, Türkoglu G, et al. . 
The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant. 2012;27(3):929–936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21742784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T.
Expanding roles of the hypoxia-response network in chronic kidney disease. Clin Exp Nephrol. 2016;20(6):835–844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26857707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan J.
Roxadustat and anemia of chronic kidney disease. N Engl J Med. 2019;381(11):1070–1072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31340090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumoto M, Makino Y, Tanaka T, et al. . 
Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. JASN. 2003;14(7):1825–1832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12819242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T, Matsumoto M, Inagi R, et al. . 
Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 2005;68(6):2714–2725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16316346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatt K, Wei Q, Pabla N, et al. . 
MicroRNA-687 induced by hypoxia-inducible factor-1 targets phosphatase and tensin homolog in renal ischemia-reperfusion injury. J Am Soc Nephrol. 2015;26(7):1588–1596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4483585</ArticleId>
            <ArticleId IdType="pubmed">25587068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai T, Ke Q, Fang Y, et al. . 
Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020;11(5):390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7242894</ArticleId>
            <ArticleId IdType="pubmed">32444604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapitsinou PP, Sano H, Michael M, et al. . 
Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J Clin Invest. 2014;124(6):2396–2409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4092875</ArticleId>
            <ArticleId IdType="pubmed">24789906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Q, Sun H, Song S, et al. . 
MicroRNA-668 represses MTP18 to preserve mitochondrial dynamics in ischemic acute kidney injury. J Clin Invest. 2018;128(12):5448–5464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6264638</ArticleId>
            <ArticleId IdType="pubmed">30325740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castiglioni L, Pignieri A, Fiaschè M, et al. . 
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. J Hypertens. 2018;36(5):1129–1146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29278547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur J, Kaur T, Sharma AK, et al. . 
Fenofibrate attenuates ischemia reperfusion-induced acute kidney injury and associated liver dysfunction in rats. Drug Dev Res. 2021;82(3):412–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33226649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu N, Wang Q, Jiang S, et al. . 
Fenofibrate improves vascular endothelial function and contractility in diabetic mice. Redox Biol. 2019;20:87–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6174921</ArticleId>
            <ArticleId IdType="pubmed">30296701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lakhia R, Yheskel M, Flaten A, et al. . 
PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice. Am J Physiol Renal Physiol. 2018;314(1):F122–f131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5866355</ArticleId>
            <ArticleId IdType="pubmed">28903946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han SH, Quon MJ, Koh KK.. 
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension. 2005;46(5):1086–1092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16230515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kostapanos MS, Florentin M, Elisaf MS.. 
Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43(5):522–531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23480615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiaravalli M, Rowe I, Mannella V, et al. . 
2-Deoxy-d-Glucose ameliorates PKD progression. J Am Soc Nephrol. 2016;27(7):1958–1969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4926967</ArticleId>
            <ArticleId IdType="pubmed">26534924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Ma Y, Zhang Y, et al. . 
Low-dose 2-deoxyglucose and metformin synergically inhibit proliferation of human polycystic kidney cells by modulating glucose metabolism. Cell Death Discov. 2019;5:76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6411866</ArticleId>
            <ArticleId IdType="pubmed">30886744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lian X, Wu X, Li Z, et al. . 
The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br J Pharmacol. 2019;176(5):711–724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6365356</ArticleId>
            <ArticleId IdType="pubmed">30515768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang AG, Diamond M, Waddell J, et al. . 
Effect of acetyl-L-carnitine used for protection of neonatal hypoxic-ischemic brain injury on acute kidney changes in male and female rats. Neurochem Res. 2019;44(10):2405–2412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7393765</ArticleId>
            <ArticleId IdType="pubmed">31041669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calabrese V, Rizza V.. 
Formation of propionate after short-term ethanol treatment and its interaction with the carnitine pool in rat. Alcohol. 1999;19(2):169–176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10548162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones LL, McDonald DA, Borum PR.. 
Acylcarnitines: role in brain. Prog Lipid Res. 2010;49(1):61–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19720082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Annadurai T, Vigneshwari S, Thirukumaran R, et al. . 
Acetyl-L-carnitine prevents carbon tetrachloride-induced oxidative stress in various tissues of wistar rats. J Physiol Biochem. 2011;67(4):519–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21618017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wrigley A, Wilkinson S, Appleby JB.. 
Mitochondrial replacement: ethics and identity. Bioethics. 2015;29(9):631–638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4620703</ArticleId>
            <ArticleId IdType="pubmed">26481204</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
